The Board of Jubilant Pharmova at its meeting held on 29 May 2024 has accepted the resignation of Jinang Pratap Parekh (DIN:10366075), as Director of the Company with effect from 31 May 2024. The Board also approved the appointment of Dr. Arul Ramakrishan (DIN: 08236356) as an Additional Director and Whole-Time Director of the Company with effect from 01 June 2024. Powered by Capital Market - Live News

Net Loss of Jubilant Pharmova reported to Rs 58.60 crore in the quarter ended March 2024 as against net loss of Rs 97.90 crore during the previous quarter ended March 2023. Sales rose 5.15% to Rs 1746.40 crore in the quarter ended March 2024 as against Rs 1660.90 crore during the previous quarter ended March 2023.For the full year,net profit reported to Rs 77.10 crore in the year ended March 2024 as against net loss of Rs 61.00 crore during the previous year ended March 2023. Sales rose 6.84% to Rs 6644.80 crore in the year ended March 2024 as against Rs 6219.30 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales1746.401660.90 5 6644.806219.30 7 OPM %15.5413.20 -13.5612.48 - PBDT216.20184.80 17 721.30638.60 13 PBT115.20-86.40 LP 339.4084.60 301 NP-58.60-97.90 40 77.10-61.00 LP Powered by Capital Market - Live News

Jubilant Pharmova announced that the Board of Directors of the Company at its meeting held on 29 May 2024, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 500%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Jubilant Pharmova reported to Rs 32.50 crore in the quarter ended March 2024 as against net loss of Rs 30.80 crore during the previous quarter ended March 2023. Sales rose 6.49% to Rs 201.70 crore in the quarter ended March 2024 as against Rs 189.40 crore during the previous quarter ended March 2023.For the full year,net profit declined 36.67% to Rs 31.60 crore in the year ended March 2024 as against Rs 49.90 crore during the previous year ended March 2023. Sales declined 2.48% to Rs 755.20 crore in the year ended March 2024 as against Rs 774.40 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales201.70189.40 6 755.20774.40 -2 OPM %6.051.11 -2.180.40 - PBDT54.2010.10 437 90.00122.50 -27 PBT41.50-1.20 LP 41.7079.30 -47 NP32.50-30.80 LP 31.6049.90 -37 Powered by Capital Market - Live News

Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 29 May 2024.Powered by Capital Market - Live News